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Insights From a Virtual World*
Stephen J. Nicholls, MBBS, PHD
leveland, Ohio
For more than half a century, angiography has been widely
used to diagnose and quantify the extent of obstructive
disease within the coronary arteries. As a result, angiography
is used to triage patients to a range of medical and
revascularization strategies. This has largely been fueled by
advances in bypass surgery and percutaneous coronary in-
tervention (PCI), and by the observation of a relationship
between the extent of angiographic disease and clinical
outcome. Accordingly, coronary angiography has become an
essential clinical tool for the cardiologist in the evaluation of
patients with ischemic symptoms.
See page 503
At the same time, however, we began to appreciate that
angiography has its limitations. It involves an invasive proce-
dure, thus limiting its use to patients with suspected ischemic
symptoms. Numerous reports emerged that many patients
with myocardial infarction had culprit lesions that were min-
imally diseased on angiography (1). This was largely explained
y the importance of plaque composition in determining the
ropensity to develop acute ischemic events and by the under-
tanding that angiography only images the lumen and fails to
isualize the vessel wall, the site where plaque accumulates.
mmense interest subsequently developed in the need to
evelop novel imaging modalities that could provide poten-
ially more important insights.
Developing new imaging modalities has had 2 major
bjectives. First, can we perform imaging in a noninvasive
ashion? This would theoretically broaden the scope of
ndividuals who could be imaged, potentially including
hose who are deemed to be of intermediate risk by
onventional risk prediction algorithms. Developments in
arotid intimal medial thickness and coronary calcification
ave been reported to provide incremental risk prediction,
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vidence from clinical trials that their use is either cost-
ffective or makes a definitive change to the management or
utcome of patients. A positive finding from such a study
ould represent a major advance for the cause of integrating
oninvasive arterial imaging into risk prediction algorithms.
n a similar fashion, there has been interest in the develop-
ent of computed tomography and magnetic resonance
maging to noninvasively image atherosclerotic plaque, al-
hough limited resolution continues to plague their ability to
isualize coronary plaque with the accuracy required by a
seful clinical tool. Nevertheless, there remains optimism
hat ongoing advances may overcome these challenges.
The second major objective in advancing arterial wall
maging has been the ability to characterize plaque compo-
ition. Moving beyond demonstrating plaque burden to
mage its individual components is based on the premise
hat a plaque containing greater amounts of lipids, inflam-
atory cells, and necrotic material is more likely to rupture
nd promote acute ischemia (2). Intravascular ultrasound
ermits imaging of the full extent of plaque in the artery wall
nd has provided important insights into the vascular changes
ollowing PCI and factors that slow progression of atheroscle-
osis. Yet, the inability to optimally characterize plaque com-
osition has limited its ability to precisely characterize the
ompositional changes within the artery wall.
Technological advances in radiofrequency analysis of ultra-
ound backscatter enable generation of a spectral tissue map
hat separates plaque into fatty, fibrofatty, necrotic, and calcific
omponents. The early experience imaging human coronary
rteries ex vivo revealed good correlation between the features
emonstrated by the virtual histology–intravascular ultrasound
VH-IVUS) approach and histology (3). This finding stimu-
ated considerable optimism that this approach would become
useful tool to the clinician, vascular biologist, and drug
eveloper in their evaluation of coronary atherosclerosis.
Since its development, VH-IVUS has been increasingly
sed in case-control studies to characterize the relationship
etween clinical characteristics and plaque components. These
eports have demonstrated the presence of more necrotic
aterial in patients with acute coronary syndromes compared
ith patients with stable symptoms and in patients with a
reater number of comorbid cardiovascular risk factors (4).
uch volumetric measures have been incorporated in clinical
rials to demonstrate potential efficacy of a novel anti-
nflammatory therapy (5). An alternative approach has been to
lassify focal lesions into a number of plaque subtypes, the most
linically important proposed to be the virtual histology–
ntravascular ultrasound-derived thin-cap fibroatheroma (VH-
CFA), identified on the basis of large plaque burden and
ecrotic core size, with no overlying fibrous tissue demonstra-
le (6). Therefore, VH-IVUS has evolved to provide a range of
ethods to characterize plaque composition in different clinical
nd therapeutic settings.
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512In this issue of JACC: Cardiovascular Interventions, Zheng
et al. (7) provide further insights into the findings of
H-IVUS in patients with the metabolic syndrome. Mul-
ivessel ultrasonic imaging was performed in 63 patients
ith angiographic coronary artery disease at a single center.
lthough the number of subjects was relatively small,
atients with either diabetes or the metabolic syndrome
ere found to have not only more atherosclerotic plaque,
ut, in particular, more necrotic and calcific material and
laques classified as VH-TCFA. These are interesting obser-
ations that provide further mechanistic support linking the
etabolic syndrome to adverse cardiovascular outcomes. How-
ver, the challenge remains to determine whether these features
elate specifically to the presence of the metabolic syndrome or
hether they simply reflect the presence of its individual
omponents. The findings of similar reports that have focused
n either plaque burden or cardiovascular outcomes would
uggest that it simply represents the impact of multiple risk
actors, rather than an independent entity (8,9). Regardless,
the findings support the concept that patients meeting the
diagnostic criteria for the metabolic syndrome warrant more
intensive management of their global cardiovascular risk.
So how does one interpret the findings of studies such as
these? In many of these reports, the differences in the size of
necrotic core appear relatively small, while maintaining statis-
tical significance. The question is to what degree does that
translate to clinical significance? The PROSPECT (Providing
Regional Observations to Study Predictors of Events in the
Coronary Tree) trial (10) investigators recently aimed to
provide clarity with regard to this issue. In a report of 697
patients undergoing multivessel imaging following PCI for an
acute coronary syndrome, the presence of a VH-TCFA was
associated with a more than 3-fold greater likelihood of
subsequent major adverse cardiovascular event (10). Though
this provides some degree of clinical link to the imaging
findings, it is important to note that this reflected observations
of very focal lesions, whereas most reports using VH-IVUS,
such as reported by Zheng et al. (7) focus on the percentage of
laque occupied by various components throughout a segment of
essel. The degree to which small differences in these parameters
elate to clinical outcome remains to be determined. Given the
mmense interest in use of this technology to evaluate novel
ntiatherosclerotic therapies in early stages of clinical development,
his will be important to establish and quickly!
The increasing use of VH-IVUS in clinical trials presents a
umber of ongoing challenges. Use of volumetric measures
ay seem relatively straightforward, but with no robust evi-
ence of a clear link between small changes in individual
omponents and clinical outcome, it remains to be determined
ow to interpret these findings. In contrast, a focal approach
ay potentially have more evidence supporting a correlation
ith clinical outcome; the difficulty matching focal lesions and
nding that these lesions often “disappear” on serial evaluation
akes it difficult to know what information this will provide.ore serial clinical data are clearly required linking changes of
hese parameters to changes in established biochemical param-
ters, measures of plaque burden, and clinical events.
More important, how does one integrate such findings into
heir clinical practice? Does the presence of more necrotic
aterial or a VH-TCFAmake an argument for intensification
f medical therapy or use of experimental, focally based
herapeutic approaches? The trend toward more aggressive use
f lipid-lowering therapy would suggest that radiofrequency
nalysis is unlikely to be necessary for this. Similarly, more
ggressive use of PCI or experimental intravascular therapies
equires definitive evidence from clinical trials that they reduce
ardiovascular morbidity before they can be advocated. For the
ime being, it would appear that although the virtual world can
rovide important insights into reality, much more work is
eeded for us to know what to do with these findings.
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